India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

About 71% of U.S. adults are either overweight or obese, according to the Centers for Disease Control. That makes it easy to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Frankly: Yes. The people who go to fine dining restaurants are, by definition, rich. They can all afford Mounjaro and Ozempic. And most are a little concerned about their weight. They have already ...

Omada Health is launching new AI tools for nutrition care after filing its S-1 to go public.

A miracle drug just wiped out WeightWatchers International’s (WW) 60-year empire. Here’s how Ozempic disrupted the weight ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...